Latest Conference Articles

NK Cells Plus Bispecific Antibody Delivers Strong Results in Advanced Lymphoma

The innate cell engager AMF13 combined with preactivated and expanded natural killer (NK) cells induced “very encouraging activity” in patients with heavily pretreated lymphoma.

Pembrolizumab Maintains Survival Benefits in 4-year Follow-Up of KEYNOTE-042 in NSCLC in China

First-line pembrolizumab monotherapy continued to elicit an overall survival benefit and durable tumor response vs standard-of-care platinum-based chemotherapy in Chinese patients with untreated PD-L1–positive, advanced or metastatic non–small cell lung cancer without sensitizing EGFR or ALK mutations.

Temferon Displays Activity in Glioblastoma

Temferon, genetically modified Tie2-expressing monocytes targeting interferona2, showed the potential to activate the immune system and reprogram the tumor microenvironment in patients with glioblastoma.

Patient Goals and Characteristics Play an Outsized Role in Determining First-Line Treatment for mCRC

Selecting the optimal frontline treatment regimen for patients with unresectable metastatic colorectal cancer requires careful consideration of multiple patient and treatment characteristics.

Biomarkers Continue to Play a Pivotal Role in Treatment Decisions in Metastatic CRC

The expansion of the treatment armamentarium has emphasized the importance of genetic testing in patients with metastatic colorectal cancer, according to Christopher Lieu, MD, who added continued developments in the field have produced additional treatment regimens across patient subsets.

Marshall Highlights the Importance of Distinct Approaches to GI Cancers

Distinctions in histology, molecular profiles, and tumor location have set diverging course of care for the treatment of patients with gastrointestinal cancers.

Maintenance Niraparib Given at Individualized Starting Dose Improves PFS in Ovarian Cancer

When maintenance niraparib was administered at an individualized starting dose, it resulted in a statistically significant and clinically meaningful improvement in progression-free survival vs placebo in patients with newly diagnosed ovarian cancer, irrespective of biomarker status.

Maintenance Selinexor Improves PFS Vs Placebo in Advanced or Recurrent Endometrial Cancer

Maintenance selinexor monotherapy was found to improve progression-free survival over placebo in patients with advanced or recurrent endometrial cancer.

IP Carboplatin/Paclitaxel Improves PFS, But Not OS, Vs IV Chemo in Ovarian Cancer

The use of intraperitoneal carboplatin with paclitaxel improved progression-free survival, but not overall survival, vs intravenous chemotherapy in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Mirvetuximab Soravtansine Elicits Encouraging ORR in FRα-High, Platinum-Resistant Ovarian Cancer

Mirvetuximab soravtansine was found to produce clinically meaningful antitumor activity with acceptable safety and tolerability in patients with platinum-resistant ovarian cancer and high folate receptor–alpha (FRα) expression.

Nemvaleukin Alfa/Pembrolizumab Combo Shows Promising Activity in Platinum-Resistant Ovarian Cancer

The combination of nemvaleukin alpha and pembrolizumab led to encouraging clinical activity in patients with pretreated ovarian cancer who are resistant to platinum-based chemotherapy.

Atezolizumab Plus Chemoradiation Triggers T-Cell Clonal Expansion in Locally Advanced Cervical Cancer

Atezolizumab given as an immune primer or concurrently with extended field chemoradiation demonstrated favorable progression-free survival and few dose-limiting toxicities, with evidence of T-cell clonal expansion in the tumors and peripheral blood of patients with locally advanced, node-positive cervical cancer.

Neoadjuvant Niraparib Shows Early Promise in BRCA-Mutated, HRD+ Ovarian Cancer

Neoadjuvant niraparib induced strong results for patients with BRCA-mutant, homologous repair deficient–positive advanced resectable ovarian cancer.

Niraparib Plus Bevacizumab Shows Promise in High-Risk Ovarian Cancer Population

Niraparib in combination with bevacizumab was efficacious following 1 line of platinum-based chemotherapy among patients with newly diagnosed advanced ovarian cancer, regardless of biomarker status.

Intravenous Chemo/Bevacizumab Shows Comparable Survival Outcomes Vs Intraperitoneal Regimen in Advanced Ovarian Cancer

Intravenous chemotherapy plus bevacizumab did not demonstrate differences in progression-free and overall survival compared with intraperitoneal chemotherapy plus bevacizumab in patients with advanced ovarian cancer with no macroscopic disease.

Olaparib Shows Comparable OS to Chemotherapy in BRCA+, Platinum-Sensitive, Relapsed Ovarian Cancer

Single-agent olaparib generated similar overall survival compared with non-platinum chemotherapy in heavily pretreated patients with platinum-sensitive, relapsed ovarian cancer with BRCA mutations, according to the final analysis of the phase 3 SOLO3 trial.

PRO Data Support the Use of Pembrolizumab Combo in Persistent, Recurrent, or Metastatic Cervical Cancer

Patient-reported outcome data support a favorable benefit/risk profile for the combination of pembrolizumab plus chemotherapy, with or without bevacizumab, in patients with persistent, recurrent, or metastatic cervical cancer.

Ociperlimab/Tislelizumab Combo Under Exploration in Previously Treated Recurrent or Metastatic Cervical Cancer

The addition of ociperlimab to tislelizumab is under investigation in the phase 2 AdvanTIG-202 trial in patients with previously treated recurrent or metastatic cervical cancer.

Antolitinic/Sintilimab Combination Under Investigation for OCCC in China

Chinese investigators have launched CC-ANNIE, a phase 2 trial exploring anlotinib plus sintilimab for women with recurrent platinum-resistant ovarian clear cell carcinoma.

Real-World Analysis Shows Survival Benefit With Second-Line PARP Maintenance Over Active Surveillance in Ovarian Cancer

Patients with recurrent ovarian cancer who received PARP inhibitor maintenance treatment in the second-line setting experienced a longer time to next treatment and overall survival compared with those who were just under active surveillance.

Precision Medicine Takes Hold of Prostate Cancer Management

The applications for germline and somatic genetic testing in prostate cancer have skyrocketed, carving out an important role in screening, diagnosis, and treatment.

Navigating Frontline RCC Treatment Paths Relies on Risk Stratification

Primo Nery Lara Jr, MD, provides an overview of the treatment landscape for patients with metastatic renal cell carcinoma.

Investigators Look Beyond Immune Checkpoint Inhibitors to Chase Moving Targets in Prostate Cancer

Immune checkpoint inhibitors represent only one area of effective therapy for patients with advanced prostate cancer, but they are not “be all, end all” of immunotherapy options.

ADT-Based Combinations Have Become Standard Therapy for Metastatic Castration-Sensitive Prostate Cancer

Overwhelming evidence has pointed to the use of androgen deprivation therapy in combination with 1 or 2 other agents as the standard of care for patients with metastatic castration-sensitive prostate cancer.

Neoadjuvant Chemotherapy Benefit Retains Stronghold for Patients With MIBC, UTUC

Effective treatment paths leveraging neoadjuvant chemotherapy have been well-established for patients with muscle-invasive bladder cancer, with mounting retrospective and prospective data continuing to demonstrate overall survival benefit compared with adjuvant chemotherapy.

Immunotherapy and Targeted Treatment Approaches Improve Outcomes in Metastatic Urothelial Cancer

Patients with metastatic urothelial carcinoma have multiple effective treatment options approved in both the first line and relapsed settings, with other promising agents and combinations currently in development.

Biomarkers Allow for Tailoring TNBC Treatments

Several factors aid treatment selection for patients with newly diagnosed metastatic triple-negative breast cancer, with upfront PD-L1 and BRCA testing being the most critical biomarkers to examine.

Abemaciclib/Endocrine Therapy Combo Showcases Long-Term Clinical Benefit in HR+ High-Risk Early Breast Cancer

The combination of adjuvant abemaciclib and endocrine therapy led to a clinically meaningful benefit at 3 years in patients with hormone receptor–positive, HER2-negative, node-positive, early breast cancer.

Addressing Cardiotoxicity in Breast Cancer Requires Multifaceted Approach

Clinicians with patients who are experiencing cardiotoxicity as a result of their breast cancer treatment should address the cardiotoxicity using a team-oriented approach based on guideline-directed therapies.

Elacestrant Significantly Improves PFS Over SOC in Advanced ER+ Metastatic Breast Cancer

Elacestrant was found to result in a statistically significant and clinically meaningful improvement in progression-free survival over standard-of-care treatment in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who previously received CDK4/6 inhibitors.